+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma



Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma



Haematologica 86(3): 274-281



Background and Objectives. Interleukin-10 (IL-10) is a pleiotropic cytokine which increases bcl-2 levels and protects cells from steroid or doxorubicin-induced apoptosis. Hodgkin and Reed-Sternberg (HRS) cells bear functional IL-10 receptors. Thus serum IL-10 (sIL-10) might inhibit apoptosis in HRS cells, which could occur as a result of either chemotherapy or the crippled immunoglobulin genes. Design and Methods. We determined sIL-10 levels in 122 patients with Hodgkin's lymphoma (HL), treated with ABVD or equivalent regimens with or without radiotherapy, and correlated them with presenting clinical and laboratory features, as well as failure-free survival (FFS) and overall survival. Results. Elevated sIL-10 levels (gtoreq10pg/mL) were detected in 55 patients (45%), and were correlated with advanced stage and elevated serum beta2-microglobulin levels. At 7 years FFS was 85% vs. 63% for patients with normal vs. elevated sIL-10 levels, respectively (p=0.01); overall survival was 97% vs. 73% (p=0.005). Multivariate analysis with Cox's proportional hazards model demonstrated that elevated sIL-10 levels were the strongest independent predictor of FFS, and were also associated with inferior overall survival. Interpretation and Conclusions. We conclude that sIL-10 levels are elevated in 45% of patients with HL, and are associated with inferior FFS and overall survival, independently of other established prognostic factors.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011348557

Download citation: RISBibTeXText

PMID: 11255274


Related references

Are the high serum interleukin-6 and vascular endothelial growth factor levels useful prognostic markers in aggressive non-hodgkin lymphoma patients?. Turkish Journal of Haematology 32(1): 21-28, 2015

Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leukemia and Lymphoma 49(11): 2091-2098, 2008

Serum interleukin-10 levels are a potent, independent prognostic factor for Hodgkins lymphoma , treated with standard chemotherapy regimens. Blood 96(11 Part 1): 727a, November 16, 2000

Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82(7): 2169-2174, 1993

Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia 17(12): 2513-2516, 2003

Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma. Asian Pacific Journal of Cancer Prevention 10(4): 669-674, 2009

Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. Tumour Biology 24(1): 53-60, 2003

Serum Soluble CD27, but Not Thymidine Kinase, Is an Independent Prognostic Factor for Outcome in Indolent Non-Hodgkin’s Lymphoma. Tumor Biology 24(1): 53-60, 2003

Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma. Cytokine 43(1): 71-75, 2008

Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. European Journal of Haematology 68(2): 91-100, 2002

HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. Journal of Clinical Oncology 25(21): 3101-3108, 2007

Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma. Annals of Oncology 2 Suppl 2: 43-47, 1991

Serum phospholipid eicosapentaenoic acid as the prognostic factor in patients with non Hodgkin's lymphoma. 2007

Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. American Journal of Clinical Oncology 25(6): 570-572, 2002

The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-Hodgkin lymphoma. Clinical Lymphoma, Myeloma and Leukemia 14(1): 43-49, 2014